About KalVista
KalVista is a company based in Cambridge (United States) founded in 2011 was acquired by Chiesi Pharmaceuticals in April 2026.. KalVista has raised $13.18 million across 3 funding rounds from investors including Chiesi Pharmaceuticals, RA Capital and Longwood Fund. The company has 270 employees as of April 30, 2024. KalVista offers products and services including Sebetralstat. KalVista operates in a competitive market with competitors including Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
- Headquarter Cambridge, United States
- Employees 270 as on 30 Apr, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Kalvista Pharmaceuticals, Inc.
-
Annual Revenue
$00as on Apr 30, 2024
-
Net Profit
$-183.44 M-44.85as on Apr 30, 2025
-
EBITDA
$-192.07 M-29.7as on Apr 30, 2025
-
Total Equity Funding
$13.18 M (USD)
in 3 rounds
-
Latest Funding Round
$33 M (USD), Post-IPO
Jul 22, 2015
-
Investors
Chiesi Pharmaceuticals
& 6 more
-
Employee Count
270
as on Apr 30, 2024
-
Acquired by
Chiesi Pharmaceuticals
(Apr 29, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of KalVista
KalVista is a publicly listed company on the NASDAQ with ticker symbol KALV in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of KalVista
KalVista offers a comprehensive portfolio of products and services, including Sebetralstat. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Oral inhibitor targeting Factor XIIa for HAE treatment.
Unlock access to complete
Unlock access to complete
Leadership Team
38 people
Sales and Marketing
9 people
Operations Team
5 people
Finance and Accounting
5 people
Software Development Team
5 people
Senior Team
4 people
Human Resources and Administration
4 people
Product Management Team
3 people
Unlock access to complete
Funding Insights of KalVista
KalVista has successfully raised a total of $13.18M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $33 million completed in July 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $33.0M
-
First Round
First Round
(23 Aug 2011)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2015 | Amount | Post-IPO - KalVista | Valuation |
investors |
|
| Nov, 2012 | Amount | Grant - KalVista | Valuation |
investors |
|
| Aug, 2011 | Amount | Series A - KalVista | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in KalVista
KalVista has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Chiesi Pharmaceuticals, RA Capital and Longwood Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is directed toward healthcare companies by Longwood Fund.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on tech sectors
|
Founded Year | Domain | Location | |
|
Venture capital fund focused on early-stage healthcare startups
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by KalVista
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - KalVista
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Kalvista Comparisons
Competitors of KalVista
KalVista operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| domain | founded_year | HQ Location |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| domain | founded_year | HQ Location |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for the treatment of multiple disorders
|
|
| domain | founded_year | HQ Location |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Kalvista
Frequently Asked Questions about KalVista
When was KalVista founded?
KalVista was founded in 2011.
Where is KalVista located?
KalVista is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is KalVista a funded company?
KalVista is a funded company, having raised a total of $13.18M across 3 funding rounds to date. The company's 1st funding round was a Series A of $13.18M, raised on Aug 23, 2011.
How many employees does KalVista have?
As of Apr 30, 2024, the latest employee count at KalVista is 270.
What does KalVista do?
KalVista therapies for hereditary angioedema and diabetic macular edema based on small molecule plasma kallikrein inhibitors through providing healthcare solutions, diversified pharmaceuticals, and drugs. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
Who are the top competitors of KalVista?
KalVista's top competitors include Merck, Roivant Sciences and AbbVie.
What products or services does KalVista offer?
KalVista offers Sebetralstat.
Is KalVista publicly traded?
Yes, KalVista is publicly traded on NASDAQ under the ticker symbol KALV.
Who are KalVista's investors?
KalVista has 7 investors. Key investors include Chiesi Pharmaceuticals, RA Capital, Longwood Fund, Venrock, and SV Health Investors.
What is KalVista's ticker symbol?
The ticker symbol of KalVista is KALV on NASDAQ.